Protocol H8H- CD-LAHF   
 
 
A Phase I, Multicenter, Open -Label, Parallel -Group, Pharmacokinetic Single Dose Study of Oral 
Lasmiditan in Subjects with Normal and Impaired Hepatic Function  
 
[STUDY_ID_REMOVED] 
 Approval Date: 09- Jan-[ADDRESS_457254] No COL MIG -114/H8H- CD-LAHF  
16.1 STUDY INFORMATION 
16.1.1 Protocol and Protocol Amendments  
Original Protocol CUD-P 9-453 ( COL  MIG-114) 
 
A  Pha s e  I ,  Mu l t i c en t e r ,  Op en -Lab e l ,  P a r a l l e l -G r oup ,  Pha rm a c ok in e t i c  S ing l e  D o s e  S tudy  
o f  O r a l  La sm id i t an  in  Sub j e c t s  w i th  N o rm a l  and  Impa i r ed  H ep a t i c  Fun c t i on  
P r o t o c o l  Numb e r : CUD- P9- 4 5 3  (COL  M IG - 1 1 4 )  
Inv e s t i g a t i ona l  P r odu c t :  L a sm id i t a n 
Spon s o r : CoL u c i d  Ph a rm a c e u t i c a l s ,  I n c . 
2 2 2  T h i r d  S t r e e t 
Su i t e  1 3 2 0 
C am b r i d g e ,  MA ,  [LOCATION_003] ,  02 1 4 2 
Spon s o r ’ s  c on t a c t  p e r s on :  
 
T e l .   
C e l l .   
Em a i l .   
P r o to c o l  V e r s i on D a t e 
1 . 0  O r i g in a l 2 0 1 7 /0 1 /[ADDRESS_457255] IANCE  
T h e  s t u dy  w i l l  b e  c o n d u c t e d  i n  a c c o r d a n c e  w i t h  s t a n d a r d s  o f  G o o d  C l in i c a l  P r a c t i c e ,  a s  d e f i n e d  
by  t h e  I n t e r n a t io n a l  Co n f e r e n c e  o n  H a rm o n i s a t i o n  a n d  a l l  a p p l i c a b l e  f e d e r a l  a n d  l o c a l  
r eg u l a t i o n s .  
CONF IDENT IAL ITY  STATEMENT 
Th e  i n f o rm a t i on  p rov i d e d  i n  th i s  do c um en t  i s  s t r i c t ly  c on f i d e n t i a l  an d  i s  a v a i l a b l e  f o r  r e v i ew  t o  i nv e s t ig a t o r ( s )  
a n d  t o  t h e  a pp rop r i a t e  I n d e p e n d e n t  E t h i c s  C omm i t t e e ( IEC )  o r  In s t i t u t i on a l  R ev i ew  Bo a rd  ( IRB ) .  I t  m ay  n o t  b e  
u s e d ,  d i vu l g e d ,  pu b l i s h e d  o r  o t h e rw i s e  d i s c l o s e d  w i t h ou t  t h e  w r i t t en  a u t h o r i z a t i on  f rom  A lg o r i t hm e  Ph a rm a  o r  
t h e  S pon s o r .  A l go r i thm e  Ph a rm a 
H e ad  O f f i c e 
575  A rm a n d- F r app i e r   
B l v d . 
L av a l  (Q u e b e c )  H 7V  4B3 
C a n a d a 
www . a l g oph a rm . c om 
T e l . :   
F a x :   - . ,  Al ta s cien ces  
CL IN ICAL  RESEARCH  
ALGOR ITHME  
[COMPANY_003]PHARMA  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003][COMPANY_003]
Research Protocol No CUD -P9-[ADDRESS_457256] No COL MIG-114 
Version 1 .0, 2017/ 01/[ADDRESS_457257] No COL MIG-114 
Version 1 .0, 2017/ 01/09 Page 3 
6.STUDY PROCEDURES AND GUIDELINES ................................ ................................................................ . 25 
6.1. Study Procedures  ................................ ................................ ................................................................ ........... 30 
6.1.1.  Physical Examination  ................................................................ .............................................................  30 
6.1.2.  C-SSRS Questionnaire  ................................................................ ...........................................................  30 
6.1.3.  Vital Signs  ................................ ................................ ................................................................ .............. 30 
6.1.4.  Laboratory Evaluations  ................................................................ ..........................................................  30 
[IP_ADDRESS].  Pregnancy Tests  ................................................................ ..............................................................  31 
6.1.5.  12-Lead Electrocardiogram  ................................................................ ................................ ....................  31 
6.1.6.  Follow-up Call  ................................ ................................ ................................................................ ....... 31 
6.
1.7. Pharmacokinetic Sampling  ................................................................ ................................ ..................... 31 
[IP_ADDRESS].  Sample processing, storage and shippi[INVESTIGATOR_007]  ................................ ................................ ........................ 32 
6.2. Bioanalytical Methods  ................................................................ ................................................................ ... 32 
6.
2.1. Aberrant values and retested samples  ................................ ................................................................ .... 32 
6.
2.2. Incurred sample reproducibility  ................................ ................................................................ ............. 32 
6.3. Pharmacokinetic Measurements  ................................................................ ................................ ....................  32 
7.ADVERSE EVENTS  ................................ ................................ ................................................................ .......... 33 
7.
1. Definitions  ................................ ................................................................ ................................ ..................... 33 
7.1.1.  Severity Assessment  ................................................................ ...............................................................  34 
7.1.2.  Causality Assessment  ................................................................ .............................................................  35 
7.2. Routine Reporting  ................................ ................................ ................................................................ ......... 35 
7.
3. Serious Adverse Event Reporting  ................................................................ ................................ ................. 36 
8.STATISTICAL ANALYSIS  ................................................................ ..............................................................  37 
8.1. Analysis Sets  ................................ ................................................................ ................................ ................. 37 
8.1.1.  Safety Analysis Set  ................................................................ ................................................................  37 
8.1.2.  Pharmacokinetic Analysis Set  ................................................................ ................................ ................ 37 
8.2. Sample Size Determination  ................................................................ ...........................................................  38 
8.3. Statistical Analysis  ................................ ................................ ................................................................ ........ 38 
8.
3.1. Descriptive Analysis  ................................................................ ..............................................................  38 
[IP_ADDRESS].  Safety Analyses  ................................................................ ...............................................................  38 
[IP_ADDRESS].  Pharmacokinetic Endpoint Analyses  ................................ ...............................................................  38 
8.3.2.  Statistical Methodology  ................................................................ ................................ ......................... 38 
[IP_ADDRESS].  Interim Analysis  ................................................................ ..............................................................  [ADDRESS_457258] (IRB)  ................................................................ ................................ ................. [ADDRESS_457259] No COL MIG-114 
Version 1 .0, 2017/ 01/[ADDRESS_457260] Retention  ................................ ................................ ................................................................ ........... 41 
10.5.  Monitoring of the Study  ................................................................ ................................................................  41 
11.ADMINISTRATIVE PROCEDURES  ................................ ................................................................ .............. 41 
11.1.  Adherence to Protocol  ................................................................ ................................................................ ... 41 
11
.2. Investigator Responsibilities  ................................................................ ................................ ......................... 41 
11.3.  Delegation of Investigator Duties  ................................................................ ................................ .................. 41 
11.4.  Premature Termination or Suspension of a Study  ................................ ................................ ......................... 42 
11.5.  Clinical Trial Application (CTA)  ................................................................ ................................ .................. [ADDRESS_457261] No COL MIG-114 
Version 1 .0, 2017/ 01/[ADDRESS_457262] OF IN -TEXT TABLES 
Table 1: Formulation of Lasmiditan, [ADDRESS_457263] No COL MIG-114 
Version 1 .0, 2017/ 01/09 Page 6 
STUDY SYNOPSIS 
Name [CONTACT_790]/Company:  CoLucid Pharmaceuticals, Inc.  
Name [CONTACT_185317]:  Lasmiditan  
Title of Study:  A Phase I, Multicen ter, Open -Label, Parallel -Group, 
Pharmacokinetic Single Dose Study of Oral Lasmiditan  in Subjects 
with Normal and Impaired Hepatic  Function  
Study Development Phase:  Phase I  
Objectives:  The primary objective of this study is to evaluate the 
pharmacokinetic  profile  of lasmiditan  following  a single oral 
[ADDRESS_457264] : Lasmiditan  200 mg tablets  
Dose  and Mode of 
Administration:  Single dose of 200 mg of lasmiditan  administered orally . 
Study Design:  This is a multicenter, open -label, non -randomized, parallel -group,  
single dose study . 
This study will enroll up to [ADDRESS_457265] (Group 1). To ensure subject safety, following dosing 
of the se first four subjects, a safety meeting will take place to 
review the safety data prior to dosing additional  subjects. After 
safety and PK results from the first four subjects have been 
reviewed, an additional four subjects with mild hepatic impairment 
(remainder of Group 1) will be enrolled concurrently with the 
moderated hepatic impairment group (Group 2). Thereafter, 
matched subjects with normal hepatic fu nction (Group 3) will be 
enrolled.  
All subjects will participate in one treatment period and will receive 
a single dose of lasmiditan  in the fasting state.  
Subjects will be confined to the clinic from at least 10 hours prior to 
dosing until 36  hours after drug administration.  
Duration of Study : Up to 35 days including Screening . 
Study Population:  Male and female adult subjects with normal hepatic  function and 
male and female adult patients with mild or moderate  hepatic  
impairment . Hepatic impairment will be classified using Child-
Pugh scores as follows:  -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457266] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 7 
5 to 6 points = Class A, mild hepatic impairment (Group 1);  
7 to 9 points = Class B, moderate hepatic impairment (Group 2);  
Normal hepatic function will be included in Group 3.  
Planned Number of Subjects:  The study is planned to enroll up to 24 subjects : 8 subjects with 
mild hepatic  impairment , 8 subjects with moderate  hepatic  
impairment , and 8 healthy subjects with normal hepatic  function.  
Subjects with moderate hepatic  impairment will be  enrolled as 
deter mined by [CONTACT_365579].  
Main Criteria for Inclusion:  Male or female aged   ≥ 18 years  
Body mass index   ≥ 18.5 0 kg/m2 
Non clinical significant findings  on 12 -lead electrocardiogram 
(ECG)  
For females, negative result on a pregnancy test  
Group 1 (Mild Hepatic Impairment)  
Presence of mild hepat ic impairment (Child -Pugh Class  A) 
Group 2 (Moderate Hepatic Impairment)  
Presence of moderate hepat ic impairment (Child -Pugh Class B) 
Group 3 (Normal Hepatic  Function ) 
Subjects will be matched by [CONTACT_654] (±10 years) , weight  (±20%) , and 
gender to the pooled mean values of subjects with hepatic  
impairment . 
Hepatic  function will be classified once at the Screening Visit, 
using the Child -Pugh score  for each subject.  
Procedures  and Assessments  Safety evaluations including vital signs (body temperature, pulse 
rate and blood pressure), physical exams, safety laboratory tests 
(clinical chemistry, hematology, endocrinology, urinalysis, 
pregnancy test, drug, and alcohol screen), ECGs , adverse event 
(AE) collection, and concomitant medication recording will be 
conducted prior to and during the treatment period.  
Pharmacokinetic ( PK) blood samples will be collected at predose 
and for 36 hours after dosing on Day 1; 1 8 PK blood samples wi ll 
be obtained from each patient/subject.  
Criteria for Evaluation:  Safety:  
Safety will be evaluated by [CONTACT_365580] 12 -lead safety ECGs, 
measurements of vital signs, physical examination and clinical 
laboratory tests at baseline and at various time point s during the 
study, and by [CONTACT_365581] /concomitant 
medication . 
Pharmacokinetics : -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457267] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 8 
The following plasma PK parameters of lasmiditan  will be 
calculated : Cmax, Tmax, AUC 0-T, AUC 0-∞, AUC 0-T/∞, λz, Thalf, Cl TOT/F 
and VD/F. 
Statistical Analyses:  Safety data will be listed by [CONTACT_365582]/abnormality or descriptive 
statistical summaries, as appropriate.  
PK parameters will be listed  and summarized by [CONTACT_43981]. Mean and individual plasma 
concentration -time profiles will be presented graphically.  
A regression analysis in which the Child -Pugh classification and the 
pharmacokinetic para meters are treated as continuous variables will 
be used to evaluate the relationship between hepatic function and 
the estimated pharmacokinetic parameters of lasmiditan . -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457268] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457269] OF ABBREVIATION S 
Term  Definition  
AE Adverse event  
ANOVA  Analysis of variance  
AUC  Area under the curve  
BLQ  Below the limit of quantification  
Cmax Maximum observed concentration  
CL Clearance  
C-SSRS  Columbia Suicide Severity Rating Scale  
CV Coefficient of variation  
EOI End of infusion  
GeoCV%  Percent geometric coefficient of va riation  
GeoMean  Geometric mean  
λZ Apparent terminal elimination rate constant  
LLOQ  Lower limit of quantification  
MTD  Maximum tolerated dose  
Min Minimum  
Max Maximum  
n Number of Observations  
NCA  Noncompartmental analysis  
PD Pharmacodynamic  
PK Pharmacokinetic  
QA Quality assurance  
QC Quality control  
SAP Statistical analysis plan  
SD Standard deviation  
SE Standard error  
SEM  Standard error of the mean  
SOP Standard Operating Procedure  
Thalf Apparent terminal elimination half -life 
Tmax Time to peak concentration  
U.S. United Stat es 
 ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
R e s e a r ch  P r o t o co l  No CUD- P 9- 4 5 3  
S p o n s o r  P r o j e c t  No COL  M IG -1 1 4  
 
V e r s i on  1.0 ,  201 7 / 01/ 0 9  P a g e  10  FAC IL IT IES 
AUTHOR  OF  THE  PROTOCOL :   
 
A lg o r i thm e  P h a rm a  
[ADDRESS_457270] IGATOR :   
 
A lg o r i thm e  P h a rm a  
1 2 0 0  B e aum o n t  A v e .  
M o u n t -R oy a l ,  Q u e b e c ,  C a n a d a  
H 3P  3P 1  
P h o n e :   
PR INC IPAL  INVEST IGATOR :   
N ew  O r l e a n s  C e n t e r  fo r  C l i n i c a l  R e s e a r c h  
1 9 2 8  A l c o a  H i g hw a y ,  S u i t e  1 0 7   
Kn o x v i l l e ,  TN  3 7 9 2 0  
 
 
O r l a n d o  C l in i c a l  R e s e a r c h  C e n t e r  
5 0 5 5  S o u th  O r a n g e  A v e .  
O r l a n d o ,  FL  3 2 8 0 9  
 
MED ICAL  LABORATORY* :  D y n a c a r e  S o lu t ion s  S a n t é 
4 8 5 0  D o b r in  S t .  
M o n t r e a l ,  Q u e b e c ,  C a n ad a  
H 4R  2P 8  
O r l a n d o  R e g io n a l  M e d i c a l  C e n t e r  C l in i c a l  L a b 
1 4 1 4  Ku h l  A v e   
O r l a n d o  FL  3 2 8 0 9 
L a b o r a to ry  C o rp o r a t i o n  o f  Am e r i c a  (L a pC o rp ) 
1 9 2 4  A l c o a  H i g hw a y  
Kn o x v i l l e ,  TN  3 7 9 2 0 
*S am p l e s  m a y  b e  o u t s o u r c e d  to  a f f i l i a t e d  a c c r e d i t e d  l a b o r a to ry  f a c i l i t i e s ,  i f  n e c e s s a ry .  . . . ,  Al tasc iences  
CL IN ICAL  RESEARCH  
[COMPANY_003]ALGOR ITHME  PHARMA  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
R e s e a r ch  P r o t o co l  No CUD- P 9- 4 5 3  
S p o n s o r  P r o j e c t  No COL  M IG -1 1 4  
 
V e r s i on  1.0 ,  201 7 / 01/ 0 9  P a g e  11  B IOANALYT ICAL  FAC IL ITY :   C o v a n c e  L a b o r a to r i e s  
3 3 0 1  K in sm a n  B l v d ,  
M ad i s o n ,  W I  53 7 0 4 ,  [LOCATION_003]  
 
SC IENT IF IC  AND  REGULATORY  FAC IL ITY : 
 
A lg o r i thm e  P h a rm a  
[ADDRESS_457271]  MANAGEMENT :   
A lg o r i thm e  P h a rm a  
[ADDRESS_457272] ICAL  FAC IL ITY :   
 
A lg o r i thm e  P h a rm a  
1 2 0 0  B e aum o n t  A v e .  
M o u n t -R oy a l ,  Q u e b e c ,  C a n a d a  
H 3P  3P 1  
DATA  MANAGEMENT  FAC IL ITY :  
 
A lg o r i thm e  P h a rm a  
1 2 0 0  B e aum o n t  A v e .  
M o u n t -R oy a l ,  Q u e b e c ,  C a n a d a  
H 3P  3P 1  . . . ,  Al tasc iences  
CL IN ICAL  RESEARCH  
[COMPANY_003]ALGOR ITHME  PHARMA  
[COMPANY_003]
[COMPANY_003][COMPANY_003]
R e s ea r ch  P roto co l  N °  CUD- P9- 453  
S p o n s o r  P r o j e c t  N °  COL  M JG - 1 1 4  
PROTOCOL  APPROVAL  
RESEARCH  PROTOCOL  NUMBER :  CUD -P9 -453  
Spon so r  P ro j e c t  No  COL -M IG -114  . . ,  A l tasc iences  ~ CL IN ICAL  RESEARCH  
' - , ! .  ALGOR ITHME  PHARMA  
T ITLE :  A  PHASE  I ,  MULTI CENTER ,  OPEN -LABEL ,  PARALLEL -GROUP,  
PHARMACOK INET IC  S INGLE  DOSE  STUDY  OF  ORAL  LASM ID IT  AN  IN  SUB JECTS  
W ITH  NORMAL  AND  IMP  A IRED  HEPAT IC  FUNCT ION  
W e  h av e  r e ad  th i s  s tudy  p ro to co l  a n d  ag r e e  th a t  i t  con t a in s  a l l  n e c e s s a ry  in fo rm a t ion  r equ i r ed  t o  
condu c t  t h i s  s tudy .  W e  ag re e  t o  condu c t  th e  s tudy  a c co rd ing  t o  t h i s  p ro to co l  a n d  in  a c co rd an c e  
w i th  Good  C l in i c a l  P r a c ti c e s  and  th e  app l i c ab l e  r egu l a to ry  r equ i r em en t s :  
 
Coo rd in a t ing  P r in c ip a l  In ve s t ig a to r  
A l t a s c i eo c e s  Comp any  I n c .  (  do ing  bu s in e s s  a s  A lgo r i thm e  Ph a rm a )  
 
P r in c ip a l  Inv e s t ig a to r  
New  O r l e an s  C en t e r  fo r  C l i n f o a J  R e s e a r ch  
 
Pr i n c i p a l  Inv e s t ig a to r  
O r l ando  C l in i c a l  R e s e a r ch  C ent e r  
A l' " "  c i en c e s  Comp any  In c .  (do ing  bu s in e s s  a s  A Jgo r i thm e  Ph a rm a)  
V e r s i o n  1 . 0 ,  2 0 1 7/0 1/ 0 9  D a t e  (yyyy /mm / dd )  
D a t e  (yyyy /mm /dd )  
D a t e  (yyyy /mm /dd )  
D a t e  (yyyy /mm /dd )  
P a g e  [COMPANY_003]
1 2  [COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
R e s e a r ch  P r o t o c o l  N °  CUD -P 9-4 5 3  
Spon so r  P ro j e c t  N1  COL  M IG -114  
PROTOCOL  APPROVAL  
RESEARCH  PROTOCOL  NUMBER :  CUD -P9 -453  
Spon so r  P ro j e c t  No  COL -M IG -114  - ,  A l tasciences  ~ CL IN ICAL  RESEARCH  u  ALGOR ITHME  PHARMA  
T ITLE :  A  PHASE  I ,  MULT ICENTER ,  OPEN- LABEL ,  PARALLEL -GROUP ,  
PHARMACOK INET IC  S INGLE  DOSE  STUDY  OF  ORAL  LASM ID ITAN  IN  SUB JECTS  
W ITH  NORMAL  AND  IMPA IRED  HEPAT IC  FUNCT ION  
W e  h av e  r e ad  th i s  s tudy  p ro to co l  a n d  ag r e e  th a t  i t  con t a in s  a l l  n e c e s s a ry  in fo rm a t ion  r equ i r ed  t o  
condu c t  th i s  s tudy .  W e  ag r e e  t o  condu c t  th e  s tudy  a c co rd ing  t o  t h i s  p ro to co l  a n d  i n  a c co rd an c e  
w i th  Good  C lin i c a l  P r a c t i c e s  and  th e  app l i c abl e  r egu l a to ry  r equ i r em en t s :  
 
, Coo rd in a t ing  P r in c ip a l  Inv e s t ig a to r  
A l t a s c i en c e s  Comp any  I n c .  (do ing  bu s in e s s  a s  A lgo r i thm e  Ph a rm a )  
 
P r in c ip a l  Inv e s t ig a to r  
N ew  O r l e an s  C en t e r  f o r  C l in i c a l  R e s e a r ch  
 
P r in c ip a l  Inv e s t ig a to r  
O r l ando  C l in i c a l  R e s e a r ch  C en t e r  
 
 
A l t a s c i en c e s  Comp any  I n c .  (do ing  bu s in e s s  a s  A lgo r i thm e  Ph a rm a )  
V e r s ion  1 . 0,  2017/ 0 1/ 09  D a t e  (yyyy / mm/ dd )  
D a t e  (yyyy /mm / d d )  
D a t e  (yyyy / mm/ d d )  
D a t e  (yyyy /mm / dd )  
P ag e  [COMPANY_003]
1 2  [COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
R e s ea r ch  P ro to co l  N °  CUD -P9 -453  
Spon so r  P ro j e c t  f f  COL .M IG -114  
PROTOCOL  APPROVAL  
RESEARCH  PROTOCOL  NUMBER :  CUD -P9 -453  
Spon so r  P ro j e c t  No  COL -M IG -114  A l tasc iences  
CL IN ICAL  RESEARCH  
ALGOR ITHME  PHARMA  
T ITLE :  A  PHASE  I ,  MULT ICENTER ,  OPEN -LABEL ,  PARALLEL -GROUP ,  
PHARMACOK INET IC  S INGLE  DOSE  STUDY  OF  ORAL  LASM ID IT  AN  IN  SUB JECTS  
W ITH  NORMAL  AND  I IY IPA IRED  HEPAT IC  FUNCT ION  
W e  h a v e  r e a d  th i s  s tudy  p ro to co l  and  ag r e e  th a t  i t  con t a in s  a l l  n e c e s s a ry  in fo rm a t ion  r e q u i r e d  t o  
condu c t  th i s  s t u d y .  W e  ag r e e  t o  condu c t  th e  s tudy  a c co rd ing  t o  th i s  p ro to co l  and  i n  a c co rd an c e  
w i th  Good  C l in i c a l  P r a c t i c e s  a n d  th e  app l i c ab l e  r egu l a to ry  r equ i r em en t s :  
 
 
A l t a s c i en c e s  Comp any  I n c .  (do ing  bu s in e s s  a s  A lgo r i thm e  Ph a rm a )  
N ew  O r l e an s  C en t e r  fo r  C l in i c a l  R e s e a r ch  
 
 
O r l ando  C l in i c a l  R e s e a r ch  C en t e r  
 
 
A l t a s c i en c e s  Comp any  In c .  (do ing  bu s in e s s  a s  A lgo r i thm e  Ph a rm a )  
V e r s ion  1 .0 ,  2017  /0  l  /09  D a t e  (yyyy / rnm /dd )  
D a t e  (yyyy /mm /dd )  
D a t e  (yyyy /mm /dd )  
P ag e  [COMPANY_003]
12  [COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
R e s ea r ch  P ro to co l  N °  CUD -P9 -453  
Spon so r  P ro j e c t  N '  COLM IG -114  
PROTOCOL  APPROVAL  
RESEARCH  PROTOCOL  NUMBER :  CUD -P 9 - - 4 5 3  
Spon so r  P ro j e c t  No  COL -M IG -114  - ,  A  ltasc iences  
CL IN ICAL  RESEARCH  
ALGOR ITHME  PHARMA  
T ITLE :  A  PHASE  I ,  MULT ICENTER ,  OPEN -LABEL ,  PARALLEL -GROUP ,  
PHARMACOK INET IC  S INGLE  DOSE  STUDY  OF  ORAL  LASM ID IT  AN  IN  SUB JECTS  
W ITH  NORMAL  AND  IMP  A IRED  HEPA  T IC  FUNCT ION  
On  b eh a l f  o f  th e  Spon so r ,  I  am  aw a r e  o f,  and  ag r e e  to  comp ly  w i th ,  a l l  o f  th e  p ro c edu r e s  
con t a in ed  w i th in  th i s  p ro to co l :  
D ig i ta l ly  s igned  by  [CONTACT_365583] :  cn=Be rnlce  Ku ca,  o= CoLuc ld  
Pha rmaceu t ica ls ,  Inc ,  ou,  
ema i l=bkuca@col uc id. com,  e=US  
Oa te :2017 .01 .3117 :51: 15 -05 '00 '  
 D a t e  (yyyy /mm /dd )  
 
CoLu c id  Ph a rm a c eu t i c a l s ,  I n c .  
V e r s ion  1 . 0,  2017/0 1 /[ADDRESS_457273] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 14 
1. INTRODUCTION 
1.1. Background 
C
oLucid Pharmaceuticals, Inc. (CoLucid) is developi[INVESTIGATOR_289950] (COL-144), a small molecule 
5-HT 1F receptor agonist. The chemical name [CONTACT_365601] (COL-144) is 2,4,6-trifluoro-N- [6-(1-
methy
lpi[INVESTIGATOR_119510]-4-carbonyl)pyridine-2-yl]benzamide hemisuccinate. 
Tript
ans, which are 5- HT 1B/1D receptor agonists, are well established as an acute therapy for 
mig
raine, though they are not effective in all patients or attacks. Triptans were developed as 
cerebral vasoconstrictors, mediated via their affinity for 5- HT 1B receptors located on vascular 
smooth m
uscle. Inherent in this mechanism of action is a liability for coronary vasoconstriction, 
and therefore, triptans are contraindicated in patients with cardiovascular disease. 
1.2. Nonclinical Studies 
Unlike tr
iptans, lasmiditan is a highly selective and potent agonist at the 5- HT 1F receptor with 
>470-fold higher affinity for the 5- HT 1F receptor than for 5- HT 1B /1D receptors. In preclinical 
models (rodent) of relevance to migraine, agonists selective for 5- HT 1F re ceptors inhibited 
trigeminal nociceptive processing without affecting blood vessel tone. Unlike triptans, lasmiditan 
did not constrict rabbit saphenous vein, an assay predictive of human coronary artery 
constriction. Lasmiditan is under development as a neurally acting treatment for migraine 
without the vasoconstrictor liability of triptans. 
Safety pharmacology studies (central nervous system [CNS] respi[INVESTIGATOR_696], cardiovascular, and 
renal) employing single intravenous (IV) administration of lasmiditan indicated that 
administration of lasmiditan at the intended clinically effective exposure levels is unlikely to 
produce adverse effects on cardiovascular, respi[INVESTIGATOR_365569]. Based on observations 
in mice, the neural mechanism of action of lasmiditan may, with exposure to high doses, produce 
CNS effects such as increased sensitivity to auditory stimuli, analgesia, reduced activity, 
hypothermia, and anticonvulsant activity. However, there have been no comparable observations 
in clinical studies, apart from alleviation of headache pain.  
1.3. Pharmacokinetics 
Cmax and AUC for subjects dosed orally (200 mg) were also measured in a fed/fasted study (COL 
MIG-104). During fed conditions (394.7 ng/mL and 2244 ng*h/mL, respectively) PK parameters 
were slightly increased compared to the fasted condition (322.8 ng/mL and 1892 ng*h/mL, 
respectively). Hence, food had a minor effect on the PK of lasmiditan. 
The plasma clearance (~59 L/h IV and 160 L/h oral), and the high total volume of distribution 
(~300 
L for IV and 1016 L for oral), indicated extensive distribution. There were no significant 
effects of gender or body weight on PK parameters. 
In vitro and in vivo metabolism studies have shown that the metabolic pathways of lasmiditan 
include N-oxidation, N-dealkylation, carbonyl oxidation, desaturation of the pi[INVESTIGATOR_365570], 
ketoreduction, or a combination of each. Up to [ADDRESS_457274] been detected in human 
hepatocytes, of which none were unique to human. When examined in vivo using LC-MS/MS ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457275] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 15 
analysis of human plasma samples from subjects receiving oral lasmiditan, three major 
metabolites (M7, M8, and (S,R)-M18) were detected. The relative proportions of metabolites to 
intact lasmiditan remained reasonably constant throughout the oral dose range studied and their 
PK were approximately linear. 
The half-life of the metabolites fell into two categories; the non-reduced metabolites with a half-
life similar to or only slightly longer than intact lasmiditan (~4.5 h), and the reduced metabolites 
with a half-life distinctly longer (>12 h) than that of lasmiditan.  
1.4. Clinical Information  
Five Phase [ADDRESS_457276] been 
completed with lasmiditan in the acute treatment of migraine. COL MIG-301 (SAMURAI) the 
first of two, Phase 3 randomized, double-blind, placebo controlled trials has completed in the 
[LOCATION_002]. The second confirmatory study, COL MIG-302 (SPARTAN), is ongoing in the 
US, [LOCATION_006] and [LOCATION_013] along with COL MIG-305, the open-label year long dosing study. 
Further information on the lasmiditan formulation, animal studies, and human studies can be 
found in the current Investigator’s Brochure. 
1.5. Study Rationale 
L
asmiditan is excreted through the kidneys and seems to have significant extrahepatic 
metaboli
sm. This study was designed to evaluate the effects of impaired hepatic function on 
lasmidit
an PK parameters, and on its safety. 
Re
sults of this study may provide information on lasmiditan dosing recommendations in patients 
with he
patic impairment. 
2. STUDY OBJECTIVES 
2.1.
 Primary Objective 
The
 primary objective of this study is to evaluate the pharmacokinetic profile of lasmiditan 
following a single oral [ADDRESS_457277] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457278] (Group 1). To 
ensure subject safety, following dosing of these first four subjects, a safety meeting will take 
place to review the safety data prior to dosing additional subjects. After safety and PK results 
from t
he first four subjects have been reviewed, an additional four subjects with mild hepatic 
impairment (remainder of Group 1) will be enrolled concurrently with the moderated hepatic 
impairment group (Group 2). Thereafter, matched subjects with normal hepatic function (Group 
3) will be enrolled. There will be up to 8 subjects in each of the following groups, based on 
hepa
tic function at screening: 
 Group 1: Mi ld hepatic impairment subjects (Child-Pugh Class A: 5 to 6 points) 
 Group 2: Moderate hepatic impairment subjects ( C hild-Pugh Class B: 7 to 9 points ) 
 Group 3: Healthy subjects with normal hepatic function 
 
All s
ubjects will participate in one treatment period and will receive a single dose of lasmiditan 
in the
 fasting state.  
Subjects will be confined to the clinic from at least [ADDRESS_457279]’s participation in the study will be 3 days (Day –[ADDRESS_457280] PK sa
mple taken on Day 2), not including the screening and follow-up phone call. 
3.2. Number of Centers and Subjects 
The
 study is planned to enroll up to 24 subjects in 3 centers.  Up to eight subjects will be enrolled 
in each group. Subjects who withdraw from the study may be replaced. Replacement subjects 
will be
 not enrolled for subjects who discontinue the study due to treatment-related AEs. 
An effort will be made to include subjects with high BMI, moreover, an effort will be made to 
enroll more females than males (for an approximate ratio of 60%/40%) or at least 50%/50%. 
3.3. Schedule of Drug Administration 
The
 following treatment regimen will be used: 
 Experimental treatment : L asmiditan [ADDRESS_457281] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457282]. 
4.2. Inclusion Criteria 
All su
bjects: 
1. Availability for the entire study period 
2.
 Motivated volunteer and absence of intellectual problems likely to limit the validity of 
c
onsent to participate in the study or the compliance with protocol requirements; ability 
to cooperate adequately; ability to understand and observe the instructions of the 
physician or designee 
3. Male or female volunteer 
4.
 A female volunteer must meet one of the following criteria: 
- If
 of childbearing potential – agrees to use one of the accepted contraceptive regimens 
from at lea
st [ADDRESS_457283] 
60 day
s after the dose. An acceptable method of contraception includes one of the 
following: 
 Abstinence from heterosexual intercourse 

 Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/insertable 
hormona
l birth control products, transdermal patch) 
 Intrauterine device (with or without hormones) 
 Condom with spermicide or condom with intra-vaginally applied spermicide 
- I
f of non-childbearing potential – should be surgically sterile (i.e. has undergone 
compl
ete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal 
state (at least one year without menses) 
5. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could 
be
come pregnant must meet the following criteria: ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457284] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 18 
- Participant is unable to procreate, defined as surgically sterile (i.e. has undergone a 
vasectomy within the last 6 months) 
- Participant is apt to procreate and agrees to use one of the accepted contraceptive 
reg
imens from first drug administration until 3 months after the drug administration. 
An acceptable method of contraception includes one of the following: 
 Abstinence from heterosexual intercourse. 
 Condom with spermicide or condom with intra-vaginally applied spermicide 
6.
 A male volunteer agrees to refrain from sperm donation from drug administration until 
[ADDRESS_457285] 18 years 
8.
 Volunteer with a body mass index (BMI) ≥18.5 kg/m2 
9.
 Light-, non- or ex-smokers. A light smoker is defined as someone smoking [ADDRESS_457286] 6 months before Day 1 of this 
study 
10. Willingness to adhere to the protocol requirements as evidenced by [CONTACT_365584] (ICF) duly read, signed and dated by [CONTACT_365585]: 
11. Clinical laboratory values within the laboratory's stated normal range; if not within this 
range, these must be without any clinical significance 
12. Have no clinically significant diseases captured in the medical history or evidence of 
clinically significant findings on physical examination and/or clinical laboratory 
evaluations (hematology, general biochemistry, endocrinology, electrocardiogram [ECG], 
and urinalysis) 
13. Must match by [CONTACT_547], as well as to the pooled mean values for age (± 10 years) and 
weig
ht (± 20% ) of subjects with hepatic impairment 
Hepatic I
mpaired Subjects: 
14. C
onsidered clinically stable in the opi[INVESTIGATOR_689] 
15. Presence of mild hepatic impairment (Child-Pugh Class A: 5-6 points) or moderate 
hepa
tic impairment (Child-Pugh Class B: 7-9 points) at screening (Appendix A ) 
4.3.
 Exclusion Criteria 
All S
ubjects: 
1. Females who are pregnant or are lact ating  ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457287] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 19 
2. History of significant hypersensitivity to lasmiditan or any related products (including 
excipi[INVESTIGATOR_186464]) as well as severe hypersensitivity reactions (like 
angioedema) to any drugs 
3. Suicidal tendency, history of or disposition to seizures, state of confusion, clinically 
re
levant psychiatric diseases  
4. Subject is at imminent risk of suicide (positive response to question 4 or 5 on the C-
S
SRS) or had a suicide attempt within 6 months prior to the screening visit 
5. Presence or history of any disorder (including Parkinson disease) that could interfere with 
c
ompletion of the study based on the opi[INVESTIGATOR_1237] 
6. Any history of tuberculosis and/or prophylaxis for tuberculosis 
7.
 Positive results to HIV Ag/Ab Combo tests (and HIV I & II screen at OCRC site) 
8.
 Females who are pregnant according to a positive pregnancy test 
9.
 Volunteers who took lasmiditan in the previous [ADDRESS_457288] (in another clinical trial) in the previous 
[ADDRESS_457289] already participated in this clinical study 
12. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical 
studie
s, etc.) in the previous 56 days before day 1 of this study 
Subjects with Normal Hepatic Function: 
13. S
eated pulse rate less than or equal 50 Beats per Minute (bpm) or more than 100 bpm at 
scre
ening 
14. Seated blood pressure below 90/60 mmHg or higher than 140/[ADDRESS_457290] drug 
bioavailability 
17. Presence of significant cardiovascular, pulmonary, hematologic, neurological, 
psy
chiatric, endocrine, immunologic or dermatologic disease 
18. Presence of out-of-range cardiac interval ( PR < 110 msec, PR > 220 msec, QRS < 60 
msec, QRS
 >119 msec and QTc > 450 msec for males and > 460 msec for females) on 
the scre
ening ECG or other clinically significant ECG abnormalities 
19. Maintenance therapy with any drug or significant history of drug dependency or alcohol 
abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic) 
20. Positive screening of alcohol and/or drugs of abuse ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457291] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 20 
21. Positive results to Hepatitis B surface Antigen (HBsAG (B) (hepatitis B)) or Hepatitis C 
Virus (HCV (C)) tests 
22. Any clinically significant illness in the previous 28 days before day 1 of this study 
23. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 
(CYP) enz
ymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, 
flucona
zole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP 
enz
ymes (such as barbiturates, carbamazepi[INVESTIGATOR_050], glucocorticoids, phenytoin, rifampin and 
St John’s Wort), in the previous [ADDRESS_457292]
udy 
Hepatic Impaired Subjects: 
25. S
eated pulse rate less than 40 bpm or more than 110 bpm at screening 
26. Seated blood pressure below 90/50 mmHg or higher than 170/[ADDRESS_457293] poorly controlled Type 1 or Type 2 diabetes as defined by [CONTACT_299082] A1c  10% 
31. Evide
nce of hepatocellular carcinoma present or acute hepatic disease from infection or 
drug toxicity at the time of screening 
32. P
resence of severe encephalopathy 
33. Presence of surgically-created or transjugular intrahepatic portal systemic shunts 
34. History of any major surgery within 6 months before Day 1 
35. History of bariatric surgery or any other gastrointestinal surgery that may induce 
malabsorption 
36. Estimated creatinine clearance by [CONTACT_3158]-Gault equation  40 mL/min/1.73 m2 at 
sc
reening 
37. Presence of clinically significant physical, laboratory, or electrocardiogram (ECG) 
finding that, in the opi[INVESTIGATOR_3755]/or Sponsor, may interfere with any 
aspect of study conduct or interpretation of results 
38. Subjects with acute, unstable, or untreated significant medical conditions. Subjects 
requiring treatment for hepatic impairment or other chronic disease (e.g., well-controlled 
diabetes, h
ypertension) must be on a stable treatment plan (medicines, doses, and 
regimens) for at least 2 weeks (except insulin) prior to Day [ADDRESS_457294] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 21 
during the study, and will be discussed on a case- by-case basis.  In all cases, the subjects’ 
treatment history must be reviewed and their enrollment must be agreed to by [CONTACT_365586]’s medical monitor 
39. Positive screening of alcohol and/or drugs of abuse unless results can be explained by a 
prescription medication 
40. Volunteers who donated [ADDRESS_457295]’s premature withdrawal from the study and record the 
reason in the respective subject’s study documents. Attempts should be made to have the subject 
complete the Post-Study tests or Early Termination study procedures.  
Premature withdrawal may occur for any of the following reasons: 
 A subject who experiences emesis within 5 hours following drug administration will be 
removed f
rom the study period. 
 Noncompliance with the protocol requirements 
 Diff iculties with blood collection 
 Pregnancy 

 Adverse event (AE) 

 Subject request 

 Investigator request 
 Sponsor request 
 Unanticipated event that could result in an inadequately characterized pharmacokinetic 
profile, such as a missed blood draw, an adverse event, meal deviations or concomitant 
medications. 
 Subjects who are prematurely withdrawn from the study for reasons other than safety 
may be replaced by [CONTACT_365587]’s 
discretion. ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457296] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457297] used in this study will be provided by [CONTACT_226113] a single 200 mg oral tablet. See  Table 1 for the formulation of lasmiditan. 
Tab
le 1: Formulation of Lasmiditan, 200 mg Tablets 
Component  Function  Amount 
200mg Tab let 
Intragranular Components  
Lasmiditan hemisuccinate 
a, b Active 
Ingredient  231.28 mg  
Microcrystalline cellulose 
PH102 b Filler  123.47 mg  
Starch 1500  Binder  30.0 mg  
Croscarmellose sodium  Disintegrant  22.5 mg  
Sodium lauryl sulfate  Wetting Agent  2.25 mg 
Purified water c Granulating 
Medium  Qs 
Extragranular Components  
Croscarmellose sodium  Disintegrant  31.5 mg  
Magnesium stearate 
(Non -bovine)  Lubricant  9.0 mg  
Totals  450 mg  
Film Coating Materials  
Opadry II  White 
(85F18422) d Film Coat  11.25 mg  
Purified water e Suspending 
Agent  (45.00 mg)  
a A salt correction factor for the hemisuccinate is assigned as 0.865 
b Note that the amount of lasmiditan hemisuccinate may be adjusted for purity and moisture content.  An 
adjustment will be made to the amount of microcrystalline cellulose used to maintain tablet weight.  
c Water for granulation is removed upon drying of the wet mass. 
d Opadry II White (85F18422) is prepared as a suspension at 20% w/w in Sterile Water for Injection and 
applied to a target of 2.5% weight gain. 
e The amount of water may be adjusted to facilitate suspension of the coating agent.  This water is removed 
during processing and does not appear in the final product.  
5.1.2.  Packaging and Labeling 
The Sponsor will be responsible for ensuring that the treatment is  manufactured in accordance 
with applicable G
ood Manufacturing Practice regulations and requirements. All labels for study 
drugs will meet applicable requirements of the protocol and the Canadian Health Products and 
the US Food and Drug Administration (FDA). ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457298] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 23 
5.1.3.  Storage and Handling 
Lasmiditan tablets should be stored by [CONTACT_365588] 25°C 
(77°F); excursions are permitted to +/- 15°C (59°F-104°F ). 
5.2. Method of Assigning Subjects to Treatment Groups 
No r
andomization will be performed for this study. Instead subjects will be categorized into 
either the control group of healthy volunteers with normal hepatic function, or into one of the 
two groups of subjects with varying degrees of hepatic impairment (mild or moderate hepatic 
impa
irment). 
Once a subject numbe
r has been a
ssigned to a subject, it will not be reassigned to another 
subject. Subjects who withdraw from the study may be replaced. Replacement subjects will not 
be enrolled for subjects who discontinue the study due to treatment-related toxicity. A new 
unique subject number will be assigned to the replacement subject. 
5.3. Blinding 
No unblindi
ng procedure is required, as this is an open-label study. 
5.4. Dosing and Administration 
5.4.1.
 Dispensing 
D
esignated site staff will dispense study drug in tablet form. 
Stud
y drugs will be administered to the subjects under supervision of the study center personnel. 
5.4.2. Administration Instructions 
The
 study drug will be administered orally in the morning.  
Dosing will be performed by [CONTACT_365589] [INVESTIGATOR_365571].  
Subjects will be asked to fast overnight (no food or drink, except water) prior to dosing, for a 
minimum of [ADDRESS_457299] 4 hours following drug 
administration, after which a standardized lunch will be served. A supper, a light snack and other 
meals wi
ll also be served at appropriate times thereafter, but not before 9 hours after dosing. 
Fluid intake other than water will be controlled during the housing period and for all subjects. 
Water will be provided ad libitum  until 1 hour pre-dose. The drug will be given with about 
240 mL (8 oz.) of water at room temperature. Water will be allowed ad lib itum beginning [ADDRESS_457300] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457301] 4 hours following drug 
administration, and will remain available at all times during the study. 
5.4.3. Treatment Compliance 
The
 following measures will be employed to ensure treatment compliance: 
 All doses will be administered under the supervision of the Investigator (or designee). 
 A mouth and hand c heck of all subjects will be carried out to ensure that all tablets have 
been swallowed.  
5.4.4. Study Drug Accountability 
C
omplete and accurate records of all study drugs must be kept. This includes acknowledgment of 
receipt of each shipment of study product (quantity and condition), subject dispensing records, 
and returned or destroyed study product. 
At the conclusion of the study, all unused investigational products and all medication containers 
will be
 returned to the Sponsor unless the Sponsor has approved other arrangements. Drug 
accountability will be performed at the completion of the trial. 
5.5. Prior and Concomitant Medication 
Hepa
tic-impaired subjects will be permitted to continue taking any prescription or OTC 
medication necessary for the management of their hepatic disease or other concurrent illness. 
The dosing schedules for such medications must be stable for 2  weeks before day 1 of the study 
(except for insulin) and maintained throughout the study. Minor dose changes consistent with 
treatment practices may be permitted at the discretion of the Investigator. All medications taken 
during the [ADDRESS_457302]’s CRF and reviewed by [CONTACT_3786]. When concomitant medications are administered, the indication, name, dose, route, 
and fr
equency will be recorded in each subject’s CRF. 
For healthy subjects, beside enzyme-modifying drugs that are not allowed for 28 days (refer to 
ex
clusion criteria), subjects will be requested to abstain from taking any prescription medications 
used with the intention to treat a condition for 28 days prior to dosing and during the study, 
unless judged differently by [CONTACT_079] [INVESTIGATOR_1461]. Systemic contraceptives and 
hormone r
eplacement therapy will be permitted. Subjects will also be requested to abstain from 
taking any over-the-counter (OTC) products for 7 days prior to dosing and during the study. 
They will be specifically reminded that this includes cold preparations (containing ASA), 
ac
etylsalicylic acid (ASA), vitamins and natural products used for therapeutic benefits and 
antacid preparations. Vitamins used as nutritional supplements in non- therapeutic doses (as 
judged by [CONTACT_45822] [INVESTIGATOR_1461]) may be accepted, but they must be stopped at 
least 48
 hours prior to dosing and during the study. 
If
 a medication (including OTC) other than those specified in the protocol is used afte r dosing or 
at an
y time before the end of the study, the Principal Investigator [INVESTIGATOR_50286]/or the Sponsor 
will decide whether the subject will be permitted to remain in the study, depending on the drug 
used, the time of drug intake, etc. The drug and dose will be noted. ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457303] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 25 
5.6. Study-Specific Restrictions 
 Subjects will be requested to abstain from alcohol for 48 hours prior to dosing and during 
the stud
y period. Throughout the study (including the return visits), in case of any doubt 
about alcohol consumption, a test for alcohol may be performed to confirm the 
phy
sician's judgment. 
 During the study, subjects who are light-smokers should not smoke more than 
10 c
igarettes per day. They will also be instructed to abstain from smoking for 2 hours 
prior to a
nd until 4 hours after drug administration. 
 Subjects will be requested to avoid food or beverages containing xanthines (i.e. tea, 
c
offee, cola drinks, energy drinks or chocolate) for 48 hours prior to dosing and during 
study period. 
 Subjects will be instructed to avoid food or beverages containing grapefruit and/or 
pomelo f
or 7 days prior to dosing and during study period. 
 Subjects will remain seated for the first [ADDRESS_457304]. However, should adverse events occur at any 
time, subjects may be placed in an appropriate position. Subjects will not engage in 
strenuous activity at any time during the confinement. 
 Female volunteers of childbearing potential will have to take appropriate measures to 
pr
event pregnancy for at least [ADDRESS_457305] 60 days after the drug administration, as described in 
Se
ction 4.2. 
 Male  subjects who are apt to procreate will be expected to use an acceptable 
contra
ceptive regimen from day [ADDRESS_457306] 3 months after the drug administration, as described in Section 
4.2. Condoms with spermicide will be provided to subjects upon departure from the 
cli
nical site. In addition to the use of condoms with spermicide, subjects will be informed 
that it is strongly recommended that their female partner uses one of the two methods 
listed below: 
- Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/ implantable/ insertable 
hormonal birth control products, transdermal patch). 
- Intrauterine device. 
 Male subjects must refrain from sperm donation from the screening and until at least 
[ADDRESS_457307] operating procedures (SOPs), 
which a
re available for all activities relevant to the quality of the study, will be followed during 
this study. The different parts of this study are su
mmarized in Table [ADDRESS_457308] of assessments for each study part is indicated with an "X" when the ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457309] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457310] to be performed. Any deviation from protocol should be noted in the Case 
Report Forms (CRFs) and the Sponsor should be notified. ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD- P9-[ADDRESS_457311] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457312]-
Study 
Tests or 
ETa End of Study  
Day 28 to – 1 -1 1 2 2 7 (±3)  
Review Inc/Exclusion Criteria & 
MedicalHistory  X      
Informed Consent  X      
Check -in  X     
Dosing    X    
Clinic Confinement   X X X   
Discharge     X   
Demographics  X      
C-SSRS questionnaire  X    X  
Concomitant Medication  X X X X X X 
Physical Examination  X    X  
Vital Signsb X  X  X  
Height, Weight, and BMI  X      
12-lead ECGc X  X  X  
HIV Ag/Ab Combo, HBsAg (B) (Hepatitis 
B) and HCV (C) Tests  X      
Drug and Alcoho l Screen  X X     
Pregnancy test (females)  X X   X  
Clinical Laboratory Evaluationsd X X   X  
PK Blood Samplee   X X   
Follow -up Call       X 
Adverse Events Recording  X X X X X X ..., Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD- P9-[ADDRESS_457313] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 28 
a  Early Termination (ET).  
b Vital signs will be measured prior to dosing and approximately 2 and 4 hours after study drug administration, including orthostatic blood pressure. 
c  12-lead ECG will be performed prior to dosing and approximately 2 hours after study drug administration. 
d  Clinical laboratory tests (hematology, biochemistry, coagulation (screening only), endocrinology (screening only) and urinalysis) will be performed. On 
Day -1, these will be done in the evening prior to drug administration. 
e  PK blood samples will be collected according to schedule of PK assessments in  Table [ADDRESS_457314] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457315] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 30 
6.1. Study Procedures 
Safety assessments will include physical examination, vital signs (blood pressure, heart rate, and 
body temperature), 12-lead ECG, laboratory tests (hematology, biochemistry, and urinalysis), 
and continuous adverse event (AE) monitoring. Body weight and height will be measured at 
Screening and BMI will be calculated. 
Cli
nically significant physical examination findings prior to the administration of study drug will 
be r
ecorded as a medical history; clinically significant findings after the drug administration will 
be r
ecorded as an AE. 
The laboratory tests will be carried out according to the standard operating procedures of the 
licensed medical laboratory. Abnormal results will be verified to rule out laboratory error. 
Persistent relevant abnormal values should be followed up until the cause is determined or until 
the values return to the pre-medication value. 
After the ICF is signed, information about all local and systemic clinical events, whether 
volunteered by [CONTACT_423], discovered by [CONTACT_49232], or detected through other 
means, will be collected, recorded and followed as appropriate. 
6.1.1. Physical Examination 
A c
omplete physical examination will be performed by a medically qualified and licensed 
individual as scheduled in Table 2. The physical examination will include a review of the 
following: 
head and neck, heart, lungs, abdomen and general appearance. 
Demographic data (age, gender, race, body weight adjusted for indoor clothing, height, BMI), 
and alcohol and smoking habits will be recorded. 
During study days not requiring a complete physical examination, a symptom-targeted physical 
exam should be done if a new AE is reported, if medically indicated. 
6.1.2. C-SSRS Questionnaire 
A Col
umbia Suicide Severity Rating Scale will be performed as scheduled in Table 2. 
6.1.3. Vital Signs 
Vital si
gn measurements (body temperature, pulse rate, blood pressure an d orthostatic blood 
pr
essure) are specified in Table 2. Vital signs can also be monitored during the study when 
judged necessary by [CONTACT_365590]. Vital signs are to be performed prior to 
blood draws. 
6.1.4.  Laboratory Evaluations 
Laboratory evaluations will be performed as scheduled in Table 2. The physician in charge or 
desig
nee will assess each abnormal value to determine if it is clinically significant. Postdose 
cli
nically significant laboratory values will be reported as adverse events. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457316] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 31 
 General biochemistry: Sodium, potassium, chloride, glucose, blood urea nitrogen (BUN), 
creatinine, ClCr, eGFR, total bilirubin, alkaline phosphatase, uric acid (screening only), 
AST, AL
T and albumin 
 Hematology: White cell count with differential (absolute values of neutrophil, 
l
ymphocyte, monocyte, eosinophil, and basophil), red cell count, hemoglobin, 
hemoglobin A1c, hematocrit, mean corpuscular volume (MCV), and platelets count 
 Coagulation: PT/INR and PTT levels (screening only) 

 Urinalysis: Color, appearance, specific gravity, pH, leukocyte, protein, glucose, ketones, 
bil
irubin, blood, nitrite, urobilinogen. Microscopic examination will only be performed if 
the dipstick test is outside of the reference range for leukocyte, blood, nitrite or protein 
 Endocrinology: Ferritin (screening only) 

 Serology: HIV Ag/Ab Combo, HBsAg and HCV 

 Drug Screen: Alcohol, amphetamines, barbiturates, cannabinoids (THC), cocaine, opi[INVESTIGATOR_858] 
a
nd phencyclidine (PCP) 
[IP_ADDRESS]. Pregnancy Tests 
A pregnancy test will be performed on female subjects as specified in Table 2. 
6.1.5. 12-Lead Electrocardiogram 
Twe
lve-lead ECGs will be performed as specified in Table 2. On the study days where ECGs are 
conducted, they should be scheduled prior to blood draws that occur for tha
t day, as the blood 
draws can impact the ECG reading. Subjects must be in a supi[INVESTIGATOR_19636] [ADDRESS_457317] venipuncture. However, as an option to the volunteer 
or if judged necessary by [CONTACT_49885], blood samples may be collected from an indwelling 
cannula (stylet catheter that requires no flushing), which will be placed in the forearm vein of the 
subject. Blood samples will be kept in an ice-water bath pending processing. Blood samples will 
be collected in one tube of [ADDRESS_457318] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 32 
The total volume of blood withdrawn, including ~[ADDRESS_457319].  
[IP_ADDRESS]. S
ample processing, storage and shippi[INVESTIGATOR_365572], split, stored, and shipped according to the sample processing 
instructions supplied by [CONTACT_85332]. 
6.2. Bioanalytical Methods 
Plasma lasmiditan concentrations will be measured according to a validated bioanalytical 
method.  
Samples from all subjects who received the investigational product will be assayed. 
6.2.1. Aberrant values and retested samples 
Una
cceptable values attributable to bioanalytical reasons will be determined according to the 
bioanalytical Facility’s SOPs. The method of re-assay and the acceptance criteria for selecting 
which value to report for the re-assayed samples will follow the bioanalytical Facility’s SOPs. 
All cases of re-assay will be reported in the final report. 
No samples will be repeated for pharmacokinetic reasons. 
6.2.2. Incurred sample reproducibility 
I
n order to establish the reproducibility of the assay with incurred samples, at least 10% of the 
total analyzable study samples will be selected and re-assayed. The replicate measurement is not 
to be averaged with the original one, but both values will be presented in the bioanalytical report 
with the initial value being used for PK calculations. The concentrations of the original and 
replicate samples will be tabulated, along with the percent difference between the two values. 
6.3. Pharmacokinetic Measurements 
The PK parameters are presented in  Table 4. Below limit of quantitation concentrations (coded 
BL
Q) will be treated as zero for all PK analyses. All reported sampling time deviations (see 
Section 6.1.7) will be taken into consideration for evaluation of plasma PK parameters. 
The pha
rmacokinetic parameters will be estimated using a non-compartmental approach with a 
log-linear terminal phase assumption. The trapezoidal rule will be used to estimate the area under 
the curve, and the terminal phase will be estimated by [CONTACT_365591]-linear regression model. Disposition parameters (AUC 0-∞, 
AUC 0-T/∞, λZ, Thalf, Cl TOT/F and V D/F) will not be estimated for individual concentration-time 
profiles where the terminal log-linear phase cannot be reliably characterized. 
In the case where less than [ADDRESS_457320] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 33 
Table 4. Pharmacokinetic Parameters 
PK Parameter  Definition  
Cmax  Maximum observed plasma concentration  
Tmax Time of maximum observed plasma concentration; if it occurs at more than 
one time point, T max is defined as the first time point with this value  
AUC 0-T Cumulative area under the plasma concentration time curve calculated from [ADDRESS_457321] 
observed quantifiable  plasma concentration  
AUC 0-∞ Area under the plasma concentration time curve extrapolated to infinity, 
calculated as AUC T + C LQC/λZ, where CLQC is the measured concentration at 
time T LQC  
AUC 0-T/ Relative percentage of AUC 0-T with respect to AUC 0-∞ 
λZ Apparent elimination rate constant, estimated by [CONTACT_365592] -life, calculated as ln(2)/λ Z 
ClTOT/F Apparent Total Plasma Clearance, calculated as dose  /AUC 0-∞ 
VD/F Apparent Volume of Distribution, calculated as dose  / λZ*AUC 0-∞ 
 
Additional pharmacokinetic parameters may be calculated if deemed appropriate. 
Pharmacokinetic analyses will be generated using Phoenix® WinNonlin® Version 6.3 (or higher). 
7.
 ADVERSE EVENTS 
7.1.
 Definitions 
An A
E is defined as any untoward medical occurrence in a subject administered a medicinal 
product and which does not necessarily have to have a causal relationship with this treatment. 
AEs occurring after the initiation of the treatment are referred to as treatment emergent adverse 
events (TEAEs). An AE can therefore be any unfavorable and unintended sign (for example, an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to this medicinal product. 
A suspected adverse reaction is any adverse event for which there is a reasonable possibility that 
the drug
 caused the adverse event. ‘Reasonable possibility’ means there is evidence to suggest a 
causal relationship between the drug and the adverse event. A suspected adverse reaction implies 
a lesse
r degree of certainty about causality than adverse reaction, which means any adverse event 
caused by a drug. 
An AE may be: -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457322] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 34 
 A new illness, 
 Worsening of a concomitant illnes s, 

 An effect of the study medication; it could be an abnormal laboratory value as well as a 
sig
nificant shift from baseline within normal range which the Principal Investigator [INVESTIGATOR_365573]
l qualified designate considers to be clinically important. 
Surgical procedures themselves are not AEs. They are therapeutic measures for conditions that 
required surgery. The condition for which the surgery is required is an AE, if it occurs or is 
detected during the study period. Planned surgical measures permitted by [CONTACT_154575](s) leading to these measures are not AEs, if the condition(s) was 
(were) known before the start of study treatment. In the latter case, the condition should be 
reported as medical history. 
A serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose: 
 Results in death, 

 Is life-threatening, 

 Requires inpatient hospi[INVESTIGATOR_1081], 

 Results in persistent or significant disability or incapacity (defined as a substantial 
disrupti
on of a person’s ability to conduct normal life functions), 
 Is a congenital anomaly or birth defect, 
Is an important medical event (including development of drug dependence or drug abuse) that 
may jeopardize the subject or may require intervention to prevent one of the other outcomes 
listed a
bove (according to medical judgment of the Principal Investigator). 
7.1.1. Severity Assessment 
All 
adverse events will be graded as mild, moderate, or severe according to the following 
definitions: 
Mild: Causing no limitation of usual activities; the subject may experience slight 
discomfort. 
Moderate: Causing some limitation of usual activities; the subject may experience annoying 
discomfort. 
Severe: Causing inability to carry out usual activities; the subject may experience 
intolerable discomfort or pain. 
Every effort will be made to obtain an adequate evaluation of the severity. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457323] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457324]’s clinical state or concomitant therapi[INVESTIGATOR_014].  
Furthermore, the AE appears with some degree of certainty to be 
related, based on the known therapeutic and pharmacologic actions or 
adverse event profile of the investigational product.  
In case of cessation or reduction of the dose, the AE may abate or 
resolve and it may reappear upon rechallenge.  
No Reasonable Possibility  Evidence  exists that the AE has an etiology other than the 
investigational product.  
For SAEs, an alternative causality must be provided (eg, pre -existing 
condition, underlying disease, intercurrent illness, or concomitant 
medication).  
7.2. Routine Reporting 
For the purposes of this study, the period of observation of adverse events extends from the 
screening visit until the follow-up call. During this period, all adverse events spontaneously 
reporte
d by [CONTACT_423], observed by [CONTACT_49885], or elicited by [CONTACT_365593]. 
Any AE which remains unresolved as of the last visit will require an evaluation and follow-up 
until the AE has been resolved or a reasonable explanation for its persistence found, or is deemed 
mild and safely resolving. 
In the case of AEs deemed related to the Investigational Product, every effort will be made to 
determine the final outcome. 
It is the Investigator’s responsibility to ensure subjects experiencing AE receive appropriate 
follow-up, treatment where required, and that every action is well documented. 
Subjects will be questioned on their health status at the beginning of study period and before 
departure from the clinical site. Open-ended questions will be asked. 
Subjects will be questioned on their health status at the beginning of the study period and before 
the departure from the clinical site. Open-ended questions will be asked. 
Classification will be performed by [CONTACT_1196] (SOC) and Preferred Term (PT) using 
the Medical Dictionary for Regulatory Activities (MedDRA), version 19.0 or higher. 
In general, AEs occurring secondary to other events (eg, clinical sequelae or a cascade of events) 
should be identified by [CONTACT_5252]. For example, if severe vomiting is known to result in 
deh
ydration, it is sufficient to record only vomiting as SAE or AE in the CRF. However, -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
R e s e a r ch  P r o t o co l  No CUD- P 9- 4 5 3  
S p o n s o r  P r o j e c t  No COL  M IG -1 1 4  
 
V e r s i on  1.0 ,  201 7 / 01/ 0 9  P a g e  36  m e d i c a l ly  s ig n i f i c a n t  AE s  o c c u r r i ng  s e c o n d a ry  t o  a n  i n i t i a t i n g  e v e n t  th a t  a r e  s e p a r a t e d  i n  t im e  
s h o u ld  b e  r e c o r d e d  a s  i n d e p e n d e n t  e v e n t s  o n  t h e  CRF .  
P r e g n a n cy  i n  a  f em a l e  s ub j e c t  o n  th e  s t u dy  s h a l l  b e  r e p o r t e d  t o  th e  Sp o n s o r  w i th i n  2 4  h o u r s  o f  
t h e  k n ow l e dg e  o f  i t s  o c cu r r e n c e  by  t h e  P r i n c i p a l  I n v e s t ig a t o r  o r  d e s ig n e e  ( fo r  p r eg n a n c i e s  
o cc u r r i ng  d u r i ng  t h e  c o u r s e  o f  t h e  s t u dy  o r  imm e d i a t e ly  f o l l ow i n g  t h e  e n d  o f  t h e  s t u dy ) .  B e c a u s e  
o f  t h e  p o s s i b i l i ty  t h a t  t h e  f e t u s / em b ry o  c o u l d  h a v e  b e e n  e xp o s e d  t o  th e  s t u d y  d r ug  t h r o ug h  t h e  
p a r e n t  a n d  f o r  t h e  s u b j e c t ’ s  s a f e ty ,  t h e  p r eg n a n cy  w i l l  b e  f o l low e d  u p  t o  d e t e rm in e  i t s  o u t c om e ,  
i n c l u d i n g  s p o n t a n e o u s  o r  v o l u n t a ry  t e rm i n a t io n ,  d e t a i l s  o f  b i r t h ,  p r e s e n c e  o r  a b s e n c e  o f  a ny  b i r t h  
d e f e c t s ,  c o ng e n i t a l  a n om a l i e s ,  o r  m a t e r n a l  a n d / o r  n ew b o r n  c om p l i c a t io n s .  
T h e  p r eg n a n cy  w i l l  b e  r e c o r d e d  a n d  r e p o r t e d  by  t h e  P r i n c i p a l  I n v e s t ig a t o r  o r  d e s i g n e e  t o  th e  
Sp o n s o r .  P r e g n a n cy  f o l low - u p  w i l l  a l s o  b e  pr o p e r l y  r e c o r d e d  t o  e n s u r e  q u a l i ty  a n d  c om p l e t e n e s s  
o f t h e  d a t a  b e l o ng i ng  t o  th e  s t u dy  d r ug  a n d  w i l l  i n c l u d e  a n  a s s e s sm e n t  o f  t h e  p o s s ib l e  c a u s a l  
r e l a t i o n  b e tw e e n  t h e  s t u dy  d r ug  a n d  a ny  p r eg n a n cy  o u t c om e .  A ny  SAE  e xp e r i e n c e d  d u r i ng  
p r eg n a n cy  w i l l  b e  r e p o r t e d  o n  a  SAE  R e p o r t  F o rm .  
[ADDRESS_457325] e s s  
a n d  SAE ,  a n d  a n  a s s e s sm e n t  o f  t h e  c a u s a l  r e l a t i o n sh i p  b e tw e e n  t h e  e v e n t  a nd  t h e  i nv e s t ig a t io n a l  
p r o d u c t ( s ) .  I n f o rm a t i o n  no t  a v a i l a b l e  a t  th e  t im e  o f  t h e  i n i t i a l  r e p o r t  ( e .g . ,  a n  e n d  d a t e  f o r  t h e  AE ,  
l a b o r a t o ry  v a l u e s  r e c e i v ed  a f t e r  t h e  r e p o r t ,  o r  h o s p i t a l  d i s c h a rg e  s umm a ry )  m u s t  b e  d o c um e n t e d .  
A l l  f o l low - u p  i n f o rm a t i o n  mu s t  b e  r e p o r t e d  a s  s o on  a s  t h e  r e l e v a n t  in f o  i s  av a i l a b l e .  
T h e  n o t i f i c a t io n  s h o u ld  b e  d i r e c t e d  t o  t h e  f o l l ow i n g  Sp o n s o r  r e p r e s e n t a t i v e :  
Be r n i c e  K u c a ,  H e a d  C l i n i c a l /R e g u l a t o ry  O p e r a t io n s 
CoL u c i d  Ph a rm a c e u t i c a l s ,  I n c . 
T e l .   
F a x .   
Em a i l :  
A n SAE  w i l l  b e  c o n s id e r e d  “ u n e xp e c t e d ”  i f  t h e  AE  i s  n o t  l i s t e d  i n  th e  i n v e s t ig a t o r  b r o c h u r e  o r  i s  
n o t  l i s t e d  a t  th e  s p e c i f i c i t y  o r  s e v e r i ty  t h a t  h a s  b e en  o b s e r v e d ;  o r ,  i f  a n  i n v e s t ig a t o r  b r o c h u r e  i s  
n o t  r e q u i r e d  o r  a v a i l a b l e ,  i s  n o t  c o n s i s t e n t  w i th  t h e  r i s k  in f o rm a t i o n  d e s c r i b e d  i n  th e  g e n e r a l  
i n v e s t ig a t io n a l  p l a n  o r  e l s ew h e r e  i n  th e  c u r r e n t  a pp l i c a t io n .  "U n e xp e c t e d , "  a s  u s e d  i n  t h i s  
d e f i n i t io n ,  a l s o  r e f e r s  t o  AE s  t h a t  a r e  m e n t i o n e d  in  t h e  i n v e s t ig a t o r  b r o c h u r e  a s  o c c u r r i ng  w i t h  a  
c l a s s  o f  d r ug s  o r  a s  a n t i c ip a t e d  f r om  t h e  p h a rm a c o l o g i c a l  p r o p e r t i e s  o f  t h e  d r u g ,  b u t  a r e  n o t  
s p e c i f i c a l ly  m e n t i o n e d  a s  o c c u r r i ng  w i t h  th e  p a r t i cu l a r  d r ug  u n d e r  i n v e s t ig a t io n .  - ,  Al tasc iences  
CL IN ICAL  RESEARCH  
[COMPANY_003]ALGOR ITHME  PHARMA  
[COMPANY_003]
[COMPANY_003]
Research Protocol No CUD -P9-[ADDRESS_457326] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457327] be reported in an expedited manner to the 
FDA
 and to the Health Canada Therapeutic Products Directorate (TPD). If so, Algorithme 
Pharma Inc, on the behalf of the Sponsor will report the event to the FDA, TPD, and all 
participating investigators. 
During a clinical trial conducted in Canada, it is required to inform Health Canada of any 
serious, unexpected adverse drug reaction that has occurred inside or outside Canada: 
 Where it is neither fatal nor life-threatening, within 15 days after becoming aware of the 
infor
mation; 
 Where it is fatal or life-threatening, immediately where possible and, in any event, within 
7 da
ys after becoming aware of the information; and 
 Within [ADDRESS_457328], submit as complete a 
report as possible which includes an assessment of the importance and implication of any 
findings. 
If reports of any new and unexpected AEs become available to the Sponsor during the clinical 
portion of this study (related or not to the present study), the Sponsor has to advise 
Algorithme Pharma, through its Clinical Investigator, of those events. If required by [CONTACT_1034], 
Algor
ithme Pharma may advise the Canadian authorities. 
8. STATISTICAL ANALYSIS 
8.1.
 Analysis Sets 
8.1.1.
 Safety Analysis Set 
The
 safety population will include all subjects who received the investigational product under 
study. 
8.1.2. Pharmacokinetic Analysis Set 
All su
bjects who received lasmiditan, had no major protocol deviations, and completed the 
period w
ith evaluable (sufficient and interpretable) data will be included in the PK analysis. 
Conc
entration data of the remaining subjects will be presented separately. 
If some subjects do not complete the sampling schedule resulting in an inadequately 
characterized AUC and elimination parameters, samples of these subjects could be included in 
the statistical pharmacokinetic analysis for only the C max and T max parameters. This decision is to 
be doc
umented by [CONTACT_365594]. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457329] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 38 
8.2. Sample Size Determination 
There is no formal statistical sample size calculation for this study. A sample size of 24; 
including 8 subjects/patients for each hepatic function group (8 subjects with normal hepatic 
function, 8 patients with mildly impaired hepatic function and 8 patients with moderatel y 
impa
ired hepatic function) was chosen because it is considered typi[INVESTIGATOR_365574] a drug. 
8.3. Statistical Analysis 
A de
tailed statistical analysis plan (SAP) describing the methodology to be used will be prepared 
prior to the completion of the clinical phase of the study. The sections below summarize the data 
analysis to be undertaken. 
8.3.1. Descriptive Analysis 
[IP_ADDRESS].
 Safety Analyses 
Data to be listed by [CONTACT_365595], AEs, vital 
signs, ECG parameters, and clinical laboratory evaluations. All values outside the clinical 
reference ranges will be flagged on the data listings. Other data to be listed by [CONTACT_365596], serology results, physical examination findings and concomitant 
medications. 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA Version 19.0 or higher). Concomitant medications will be coded using the World 
Health Organisation drug dictionary (WHO-DDE March 1st, 2016).  
[IP_ADDRESS]. P
harmacokinetic Endpoint Analyses 
Desc
riptive statistics will be calculated for plasma concentrations at each individual time point 
and for all PK parameters. The individual plasma concentration/time profiles will be presented 
using the a
ctual sampling times whereas the mean plasma concentration/time profiles will be 
presented using the theoretical sampling times. 
8.3.2. Statistical Methodology 
The
 natural logarithmic transformation of Cmax, AUC 0-T, AUC 0-∞, λZ, Cl TO T/F and V D/F as well as 
the ra
nk-transformation of T max will be used  for all statistical inference.  
Statist
ical analyses will be generated using validated SAS® (version 9.4 or higher). 
Regr
ession Analysis  
The Child-Pugh classification at baseline will be used the primary measure of hepatic function 
for a regression analysis to evaluate the relationships between estimated hepatic function and PK 
parameters. Hepatic function in affected subjects will be entered in separate regression models as 
the following: 
 Individual Child-Pugh scores; 

 Hepatic Impairment Group:  -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457330] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 39 
o 1: Child-Pugh classification A;  
o 2: Child-Pugh classification B;  
o
 3: Subject with normal hepatic function 
F
or each PK parameter, a regression analysis will be performed to assess the impact of impaired 
Hepatic Function, using a regression model of the form α + β*(Hepatic Function) + ε where the 
errors (ε) will be assumed to be independent and normally distributed with mean zero and 
variance σ2. The parameter β represents the correlation between the relevant PK parameter and 
the Hepatic Function which will be treated as a continuous variable. 
The hypothesis of the slope of trend being different from zero will be assumed if the two-sided 
test of the nullity of the parameter β is statistically significant at the 5% level. 
[IP_ADDRESS]. Interim Analysis 
Approximately four subjects with mild hepatic impairment will be enrolled first (Group 1). To 
ensure subject safety, following dosing of these first four subjects, a safety meeting will take 
place to review the safety data prior to dosing additional subjects. After safety and PK results 
from the first four subjects have been reviewed, an additional four subjects with mild hepatic 
impairment (remainder of Group 1) will be enrolled concurrently with the moderated hepatic 
impairment group (Group 2). Thereafter, matched subjects with normal hepatic function 
(Group 3) will be enrolled.  
Inte
rim PK analysis of subjects with mild hepatic function will be performed as described in 
Section 6.3. 
9. ETHICS 
9.1.
 Institutional Review Board (IRB) 
This protoc
ol and the ICF will be submitted to IRBs (or IECs ) (one for each study center) prior 
to initiation of the study and the study will not start until the Board has approved the documents. 
Notification of the Board’s approval will be appended to the final report. 
9.2. Ethical Conduct of the Study 
This s
tudy will be conducted in compliance with the study protocol, the ethical principles in the 
latest version of the Declaration of Helsinki, the ICH Guideline E6 for GCP, the FDA GCP Code 
of F
ederal Regulations (CFR) Title 21, part 56, European regulation EU 536/2014 and the 
Tri-Council Policy Statement (Canada). 
9.3. Participant Information and Consent 
B
efore inclusion in the study, each prospective subject will be given a full explanation of the 
purpose of the study, the procedures to be carried out and the potential hazards. Once this 
essential information is provided to the volunteer and once the physician in charge or designee 
has the conviction that the volunteer understands the implications of participating in the study, 
the volunteers will be required to read, sign and date a properly executed written informed -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457331] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457332]’s further consent 
should be obtained. 
9.4. Subject Confidentiality 
The
 Investigators and the Sponsor will preserve the confidentiality of all subjects taking part in 
the study, in accordance with GCP and local regulations. Subjects should be identified by a 
unique subject identifier on all study documents provided to the Sponsor. In compliance with 
Federal regulations/ICH GCP Guidelines, it is required that the Investigator and institution 
permit authorized representatives of the company, of the regulatory agency(s), and IRB access to 
review the subject’s original medical records for verification of study-related procedures and 
data. The investigator is obligated to inform the subject that his/her study-related records will be 
reviewed by [CONTACT_365597]. 
10. DAT A COLLECTION, RETENTION, AND MONITORING 
10.1.
 Case Report Forms 
A CR
F is a gathering of all pertinent data collected for each subject included (i.e., who received 
an 
Investigational Product treatment) in a clinical trial. Once all CRF forms (including 
multi-subject CRF forms) are completed and reviewed. At Algorithme Pharma, the complete 
CRF will be approved and signed by [CONTACT_127024], who received a signature [CONTACT_365602]. At the clinical sites, the complete CRF will be approved and 
signed by [CONTACT_079]. 
The original source documents and a copy of the corresponding CRFs will be retained by [CONTACT_3786]. Copi[INVESTIGATOR_365575]. 
10.2. Data Management and Processing 
Da
ta entry will be performed according to clinical site facility procedures. Information will be 
entered into a Medrio database, which will be used for developi[INVESTIGATOR_365576]. Appropriately trained and designated individuals will be given access to the 
database and will perform entry of the data from the CRFs. The data management process will 
comply with all regulatory standards and will use from the clinical sites for generating the final 
locked da
tabase. 
10.3. Quality Assurance 
De
signated personnel from Algorithme Pharma will be responsible for maintaining quality 
assurance (QA) and quality control (QC) systems to ensure that the trial is conducted and 
clinical/PK/statistical data are generated, documented and reported in compliance with the 
protocol and ICH Guideline E6 for Good Clinical Practices. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457333] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457334] Retention 
All essential documents and records will be maintained by [CONTACT_365598] a period of 
25 years. These documents may be retained for a longer period if required by [CONTACT_365599](s) (FDA CFR 312.57 (C)) or if needed by [CONTACT_1034]. 
10.5. Monitoring of the Study 
The
 Sponsor or its representative may visit the study facilities at any time in order to maintain 
cur
rent and personal knowledge of the study through review of the records, comparison with 
source documents, observation and discussion of the conduct and progress of the study. 
Algorithme Pharma will permit trial-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s) by [CONTACT_20618]/documents. 
11. ADMINISTRATIVE PROCEDURES 
11.1.
 Adherence to Protocol 
Ex
cluding an emergency situation in which proper treatment is required for the protection, safety 
and well-being of the study subjects, the study will be conducted as described in the approved 
protocol and performed according to ICH/GCP and FDA guidelines. Any deviation from the 
protocol will be recorded and explained. 
If amendments to the protocol and/or amendments or revisions to the ICF are required, the 
modifications will be documented and submitted to an IRB for approval. 
11.2. Investigator Responsibilities 
The form “Qualified Investigator Undertaking” will be signed by [CONTACT_365600] (being also referred to as the “Qualified 
Investigator”) at each site prior to the commencement of his responsibilities with respect to the 
cli
nical trial, as required by [CONTACT_113148]. The undertaking form will be 
maintained with the trial records and will be made available upon request. 
In addition, the FDA 1572 form, Statement of Investigator [Title 21, CFR Part 312], duly signed 
by [CONTACT_079] [INVESTIGATOR_1238]/or the Principal Investigator (if in charge of clinical assessment) 
as a c
ondition for conducting the clinical investigation will be kept on file and will be available 
upon request. 
11.3. Delegation of Investigator Duties 
The Principal Investigator [INVESTIGATOR_365577], any amendments to the protocol, the study treatments, 
and their trial-related duties and functions. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457335] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457336] or supervise any potential resuscitation procedures. 
11.4. Premature Termination or Suspension of a Study 
The S
ponsor or its representative may terminate the study at any time for scientific or corporate 
rea
sons. 
If the trial is prematurely terminated or suspended for any reason, Algorithme Pharma or the 
Principal Investigator [INVESTIGATOR_365578], should assure appropriate 
therapy and follow-up for the subjects and should inform the regulatory authority (ies) when 
required. All procedures should be done according to clinical site procedures. 
11.5. Clinical Trial Application (CTA) 
A CTA must
 be submitted to Health Canada prior to the study, and a “No Objection Letter” 
(NOL) must be obtained before any drug administration. 
11.6. Exemption Application for Controlled Substances 
This t
rial does not involve a controlled substance. 
11.7. Publications 
The
 preparation and submission for publication of a manuscript c ontaining the study results sha ll 
be in accordance with a process determined by [CONTACT_350616].  The publication or presentation of any study results shall 
comply with all applicable privacy laws. -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 
Research Protocol No CUD -P9-[ADDRESS_457337] No COL MIG-114 
 
Version 1 .0, 2017/ 01/09 Page 43 
12. REFERENCES 
Investigational Brochure, Lasmiditan (COL-144), version 8.0, February 23, [ADDRESS_457338] No COL MIG-114 
 
Version 1 .0, 2017/ 01/[ADDRESS_457339] severe derangement. 
 1 Point  2 Points  3 Points  
Bilirubin, total, μmol (mg/dL)  <34 (<2)  34-50 (2 -3) >50 (>3)  
Albumin, mg/L  >35 28-35 <28 
INR <1.7 1.71-2.20 >2.20  
Ascites  None  Suppressed with medication  Refractory  
Hepatic encephalopathy  None  Grade I -II  
(or suppressed with medication)  Grade III -IV  
(or refractory)  
Class A=5-6 points; class B=7-9 points 
INR=International Normalized Ratio 
Source: http://www.doctorslounge.com/gastroenterology/scores/child.htm  -, Altasciences 
CLINICAL RESEARCH 
ALGORITHME PHARMA 